Polarean Imaging (POLX)

Company information

Company listing information, company shareholders as well as key dates and contact details.

This share factsheet isn’t an investment recommendation. We don’t offer personal advice so if you’re unsure, please seek independent advice. Remember, the value of investments can fall as well as rise and you may get back less than you invest.

Business summary

Polarean is a clinical-stage company with a core technology that is a drug-device combination product that enables the visualisation of hyperpolarised 129Xe ("HPX") using MRI technology to help diagnose lung disease earlier, identify the type of intervention likely to benefit a patient, and to monitor the efficacy of treatment. It is currently being used at a number of research sites on a pre-FDA clearance basis to facilitate the research and evaluation of lung function, to assist in making improved disease progression assessment and to clearly visualise the effectiveness of several therapeutics which are under development.

Brands

None

Listing information

Key dates

Company shareholders

Last updated 31/12/2023

*Major shareholders are individuals or institutions that own more than 3% of the company’s shares and have been reported in the annual accounts.